• Something wrong with this record ?

Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome

K. Hronová, P. Pokorná, L. Posch, O. Slanař

. 2016 ; 65 (Suppl. 4) : S463-S472. (Selected results presented at the occasion of 66th Czech-Slovak Pharmacological Days)
. 2016 ; () : S463-S472.

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17020940

Our aim was to describe the effect of dosing and genetic factors on sufentanil- and midazolam-induced analgosedation and withdrawal syndrome (WS) in pediatric population. Analgosedation and withdrawal syndrome development were monitored using COMFORT-neo/-B scores and SOS score. Length of therapy, dosing of sufentanil and midazolam were recorded. Genotypes of selected candidate polymorphisms in CYP3A5, COMT, ABCB1, OPRM1 and PXR were analysed. In the group of 30 neonates and 18 children, longer treatment duration with midazolam of 141 h (2 - 625) vs. 88 h (7 - 232) and sufentanil of 326.5 h (136 - 885) vs. 92 h (22 - 211) (median; range) was found in the patients suffering from WS vs. non-WS group, respectively. Median midazolam cumulative doses were in the respective values of 18.22 mg/kg (6.93 - 51.25) vs. 9.94 mg/kg (2.12 - 49.83); P=0.03, and the respective values for sufentanil were 88.60 microg/kg (20.21 - 918.52) vs. 21.71 microg/kg (4.5 - 162.29); P<0.01. Cut off value of 177 hours for sufentanil treatment duration represented predictive factor for WS development with 81 % sensitivity and 94 % specificity. SNPs in the candidate genes COMT, PXR and ABCB1 affected the dosing of analgosedative drugs, but were not associated with depth of analgosedation or WS. Cumulative dose and length of analgosedative therapy with sufentanil significantly increases the risk of WS in critically ill neonates and children.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17020940
003      
CZ-PrNML
005      
20181120143315.0
007      
ta
008      
170623s2016 xr f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.933519 $2 doi
035    __
$a (PubMed)28006928
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Hronová, Karolína $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0272629
245    10
$a Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome / $c K. Hronová, P. Pokorná, L. Posch, O. Slanař
520    9_
$a Our aim was to describe the effect of dosing and genetic factors on sufentanil- and midazolam-induced analgosedation and withdrawal syndrome (WS) in pediatric population. Analgosedation and withdrawal syndrome development were monitored using COMFORT-neo/-B scores and SOS score. Length of therapy, dosing of sufentanil and midazolam were recorded. Genotypes of selected candidate polymorphisms in CYP3A5, COMT, ABCB1, OPRM1 and PXR were analysed. In the group of 30 neonates and 18 children, longer treatment duration with midazolam of 141 h (2 - 625) vs. 88 h (7 - 232) and sufentanil of 326.5 h (136 - 885) vs. 92 h (22 - 211) (median; range) was found in the patients suffering from WS vs. non-WS group, respectively. Median midazolam cumulative doses were in the respective values of 18.22 mg/kg (6.93 - 51.25) vs. 9.94 mg/kg (2.12 - 49.83); P=0.03, and the respective values for sufentanil were 88.60 microg/kg (20.21 - 918.52) vs. 21.71 microg/kg (4.5 - 162.29); P<0.01. Cut off value of 177 hours for sufentanil treatment duration represented predictive factor for WS development with 81 % sensitivity and 94 % specificity. SNPs in the candidate genes COMT, PXR and ABCB1 affected the dosing of analgosedative drugs, but were not associated with depth of analgosedation or WS. Cumulative dose and length of analgosedative therapy with sufentanil significantly increases the risk of WS in critically ill neonates and children.
650    _2
$a adjuvancia anestetická $x aplikace a dávkování $x škodlivé účinky $7 D000759
650    _2
$a dítě $7 D002648
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická variace $x genetika $7 D014644
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a midazolam $x aplikace a dávkování $x škodlivé účinky $7 D008874
650    _2
$a pediatrie $x metody $7 D010372
650    _2
$a farmakogenetika $x metody $7 D010597
650    _2
$a jednonukleotidový polymorfismus $x genetika $7 D020641
650    _2
$a abstinenční syndrom $x diagnóza $x genetika $7 D013375
650    _2
$a sufentanil $x aplikace a dávkování $x škodlivé účinky $7 D017409
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pokorná, Pavla $7 xx0122705 $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic; Clinic of Pediatric and Adolescent Medicine, General University Hospital, Prague, Czech Republic; Intensive Care and Department of P ediatric Surgery, Erasmus MC – Sophia Children's Hospital, Rotterdam, Netherlands
700    1_
$a Posch, L. $u Clinic of Pediatric and Adolescent Medicine, General University Hospital, Prague, Czech Republic
700    1_
$a Slanař, Ondřej $7 xx0058262 $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00003824 $t Physiological research. Selected results presented at the occasion of 66th Czech-Slovak Pharmacological Days $x 1802-9973 $g Roč. 65, Suppl. 4 (2016), s. S463-S472
773    0_
$t Selected results presented at the occasion of 66th Czech-Slovak Pharmacological Days $g (2016), s. S463-S472 $w MED00196536
856    41
$u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20170623 $b ABA008
991    __
$a 20181120143410 $b ABA008
999    __
$a ok $b bmc $g 1236276 $s 981813
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 65 $c Suppl. 4 $d S463-S472 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $o Selected results presented at the occasion of 66th Czech-Slovak Pharmacological Days $x MED00003824
BMC    __
$a 2016 $d S463-S472 $m Selected results presented at the occasion of 66th Czech-Slovak Pharmacological Days $x MED00196536
LZP    __
$b NLK118 $a Pubmed-20170623

Find record

Citation metrics

Archiving options